Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease
Antonio M. Gotto, Christopher P. Cannon, Xiujiang Susie Li, Sanskruti Vaidya, Uma Kher, Eliot A. Brinton, Michael Davidson, Jennifer E. Moon, Sukrut Shah, Hayes M. Dansky, Yale Mitchel, Philip Barter
Dive into the research topics of 'Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease'. Together they form a unique fingerprint.